Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy

INTRODUCTION: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinson, Lewis, Corey, Alfred, Hanfling, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766/
https://www.ncbi.nlm.nih.gov/pubmed/28856066
http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766/
https://www.ncbi.nlm.nih.gov/pubmed/28856066
http://dx.doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d

Ejemplares similares